RxDoctor Payments Data

Devang Gandhi, MD

Cardiovascular Disease · West Orange, NJNPI 1225038755

Payments from drug & device makers

$5,107in general payments, 2019–2025

Across 342 payments — averaging $14.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$892
  • Amgen$480
  • Pfizer$480
  • Merck$447
  • Johnson & Johnson$409
  • E.r. Squibb & Sons, L.L.C.$282
  • plus $2K from 33 others

What the payments were for

  • Food & beverage$5,07599%
  • Education$190%
  • Other$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,107 in reported general payments places this provider in the 65th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$305,686
Medicare patients
2,346
Services billed
4,981

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban113$148,105
Repatha SureclickEvolocumab38$38,462
EntrestoSacubitril/Valsartan19$31,690
XareltoRivaroxaban14$20,591
Carvedilol ErCarvedilol Phosphate12$6,847
Atorvastatin Calcium231$2,592
Metoprolol Succinate155$2,150
Rosuvastatin Calcium112$1,631
Amlodipine Besylate204$1,579
Carvedilol104$1,425
Amlodipine-ValsartanAmlodipine Besylate/Valsartan11$1,105
Ranolazine ErRanolazine14$1,043
Diltiazem 24hr Er (Cd)Diltiazem Hcl35$997
Ezetimibe37$901
Losartan Potassium115$890

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$480$148,105113 claims
NovartisEntresto$892$31,69019 claims
Johnson & JohnsonXarelto$409$20,59114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in West Orange

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →